International Society for the Study of Women's Sexual Health

NEWS

General Statement of the International Society for the Study of Women's Sexual Health

The International Society for the Study of Women's Sexual Health (ISSWSH), the preeminent scientific organization focused on research, education, and clinical practice of women's sexuality, applauds the FDA's recent announcement of it's upcoming Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee on June 4, 2015.

The meeting culminates the prolonged development of flibanserin, a drug that could be the first approved medical treatment for distressing low sexual desire. Flibanserin offers a favorable safety and efficacy profile for the treatment of Hypoactive Sexual Desire Disorder in women. While we fully endorse the FDA's evidence-based review of the risks and benefits of this treatment, ISSWSH wishes to emphasize the significant unmet need for safe and effective medical therapies to address all women's sexual problems.

Save the Date

ISSWSH / ISSM Joint Meeting 2019
March 7-10, 2019   19 days left
Atlanta, GA, USA
Read more...

ISSWSH Fall Course 2019
November 14-16, 2019   271 days left
DoubleTree Hilton Hotel, Scottsdale, AZ - USA
Read more...

ISSWSH Annual Meeting 2020
March 5-8, 2020   383 days left
Renaissance Orlando at Seaworld, Orlando, FL, USA

Latest Tweets

Have you purchased your copy of ISSWSH's own, "Textbook of Female Sexual Function and Dysfunction: Diagnosis and Tr… https://t.co/0z3F7f4OgX ISSWSH
Best way to teach medical students and health care providers sexual health history taking? Come to Dr Elizabeth Rub… https://t.co/zzC7emhTs9 ISSWSH
Happy Valentines Day! What are some simple ways couples can increase sexual intimacy? @drbrandon @TalliRosenbaum… https://t.co/P0QNCv35yd ISSWSH

Contact Details

ISSWSH Executive Office
14305 Southcross Dr
Suite 100
Burnsville, MN 55306
USA

Phone: +1 (952) 683 9025
Fax: +1 (952) 314 8212
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow us on Twitter!